

Original citation:

Bosch, Sofie, el Manouni el Hassani, Sofia, Covington, James A., Wicaksono, Alfian N., Bomers, Marije K., Benninga, Marc A., Mulder, Chris J. J., de Boer, Nanne K. H and de Meij, Tim G. J. (2018) *Optimized sampling conditions for fecal volatile organic compounds analysis by means of field asymmetric ion mobility spectrometry*. Analytical Chemistry. doi:[10.1021/acs.analchem.8b00688](https://doi.org/10.1021/acs.analchem.8b00688)

Permanent WRAP URL:

<http://wrap.warwick.ac.uk/103032>

Copyright and reuse:

The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions. Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available.

Copies of full items can be used for personal research or study, educational, or not-for profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

Publisher's statement:

"This document is the Accepted Manuscript version of a Published Work that appeared in final form in Analytical Chemistry. copyright © American Chemical Society after peer review and technical editing by the publisher.

To access the final edited and published work

<http://pubs.acs.org/page/policy/articlesonrequest/index.html> ."

A note on versions:

The version presented here may differ from the published version or, version of record, if you wish to cite this item you are advised to consult the publisher's version. Please see the 'permanent WRAP URL above for details on accessing the published version and note that access may require a subscription.

For more information, please contact the WRAP Team at: wrap@warwick.ac.uk

1 OPTIMIZED SAMPLING CONDITIONS FOR FECAL VOLATILE ORGANIC COMPOUNDS ANALYSIS
2 BY MEANS OF FIELD ASYMMETRIC ION MOBILITY SPECTROMETRY.

3 Sofie Bosch¹, MD*, Sofia el Manouni el Hassani⁴, MD*, James A Covington², Phd, Alfian N.
4 Wicaksono², SSi, Marije K Bomers³, MD, PhD, Marc A Benninga⁴, MD, PhD, Chris JJ Mulder,
5 MD, PhD¹, Nanne KH de Boer¹, MD, PhD**, Tim GJ de Meij⁴, MD, PhD**

6 * Shared first, listed alphabetically

7 ** Shared last, listed alphabetically

8

9 ¹Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, The
10 Netherlands

11 ²School of Engineering, University of Warwick, Coventry, United Kingdom

12 ³Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands

13 ⁴Department Pediatric Gastroenterology, Emma Children's Hospital/Academic Medical Center,
14 Amsterdam, The Netherlands

15 ⁵Department Pediatric Gastroenterology, VU University Medical Center, Amsterdam, The
16 Netherlands

17

1 **Conflicts of interest**

2 The department of Gastroenterology and Hepatology of the VU University Medical Center
3 has no conflicts of interest to disclose

4 **Financial disclosures**

5 S Bosch has nothing to declare.

6 S el Manouni el Hassani has nothing to declare.

7 JA Covington has nothing to declare.

8 AN Wicaksono has nothing to declare.

9 MK Bomers has nothing to declare.

10 CJJ Mulder has served as a principal investigator for TEVA Pharma BV. He has received a
11 research grant from TEVA Pharma BV.

12 MA Benninga has served as speaker for Abbott and FrieslandCampina. He has served as
13 consultant for Shire, Takeda, Norgine, AstraZeneca, Danone, Friesland Campina, Novalac and
14 Mead Johnson

15 NKH de Boer has served as a speaker for AbbVie and MSD. He has served as consultant and
16 principal investigator for TEVA Pharma BV and Takeda. He has received a (unrestricted)
17 research grant from Dr. Falk and Takeda.

18 TGJ de Meij has served as a speaker for Mead Johnson. He has received a (unrestricted)
19 research grant from Danone

20

1 **Author contributions**

2 TGJ de Meij and NKH de Boer were the guarantors of this article.

3 S el Manouni el Hassani and S Bosch collected the fecal samples and performed VOC
4 analysis.

5 JA Covington and AN Wicaksono analyzed the results.

6 S Bosch drafted the first version of the manuscript.

7 S el Manouni el Hassani, JA Covington, AN Wicoksono, MK Bomers, CJ Mulder, MA Benninga,

8 KHN de Boer, TGJ de Meij reviewed the manuscript for important intellectual content.

9 S Bosch finalized the manuscript.

10 All authors agreed to the final version of the manuscript.

11 **Running title** Optimized sampling conditions for fecal volatile organic compounds by means
12 of field asymmetric ion mobility spectrometry.

13

14 **Word count** 4423

15 **Version** 3.0

16 **Key words** Volatile organic compounds, VOC, Lonestar, FAIMS, Field Asymmetric Ion

17 Mobility Spectrometry, Inflammatory bowel disease,

18

1 **Corresponding author**

2 Sofie Bosch, MD

3 Department of Gastroenterology and Hepatology

4 VU University Medical Center

5 Room PK 2X 136

6 De Boelelaan 1117

7 1081 HV Amsterdam

8 T: +31 (0)20 444 07 99

9 F: +31 (0)20 444 05 54.

10 E: s.bosch1@vumc.nl

11

1 **Abstract (259 words)**

2 **Background** Fecal volatile organic compounds (VOCs) are increasingly considered as
3 potential non-invasive, diagnostic biomarkers for various gastrointestinal diseases.
4 Knowledge of influence of sampling conditions on VOC outcomes is limited. We aimed to
5 evaluate effects of sampling conditions on fecal VOC profiles and to assess under which
6 conditions an optimal diagnostic accuracy in the discrimination between pediatric
7 inflammatory bowel disease (IBD) and controls could be obtained.

8 **Methods** Fecal samples from *de novo* treatment-naïve pediatric IBD patients and healthy
9 controls (HC) were used to assess effects of sampling conditions compared to the standard
10 operating procedure (reference standard), defined as 500mg of sample mass, diluted with
11 10mL tap water, using field asymmetric ion mobility spectrometry (FAIMS).

12 **Results** A total of 17 IBD (15CD and 2 UC) and 25 HC were included. IBD and HC could be
13 discriminated with high accuracy (accuracy=0.93, AUC=0.99, $p<0.0001$). Smaller fecal sample
14 mass resulted in a decreased diagnostic accuracy (300mg accuracy=0.77; AUC=0.69, $p=0.02$;
15 100mg accuracy=0.70, AUC=0.74, $p=0.003$). A loss of diagnostic accuracy was seen towards
16 increased numbers of thaw-freeze cycles (one cycle: accuracy=0.61, AUC=0.80, $p=0.0004$,
17 two cycles: accuracy=0.64, AUC=0.56, $p=0.753$, three cycles: accuracy=0.57, AUC=0.50,
18 $p=0.5101$) and when samples were kept at room temperature for 180 minutes prior to
19 analysis (accuracy=0.60, AUC=0.51, $p=0.46$). Diagnostic accuracy of VOC profiles was not
20 significantly influenced by storage duration differences of 20 months.

21 **Conclusion** Application of 500mg sample mass analyzed after one thaw-freeze cycle, showed
22 best discriminative accuracy for differentiation of IBD and HC. VOC profiles and diagnostic
23 accuracy were significantly affected by sampling conditions, underlining the need for
24 implementation of standardized protocols in fecal VOC analysis.

1 **Introduction**

2 Analysis of volatile organic compounds (VOC) is a relatively new technique within the field of
3 metabolomics. VOCs are carbon-based chemicals originating from both physiological and
4 pathophysiological processes in the human body. Fecal VOCs are considered to reflect
5 microbiota composition, function and interaction with the host [1, 2]. They are increasingly
6 considered to have potential as biomarker in the diagnostic work-up and monitoring of
7 various gastrointestinal diseases, e.g. inflammatory bowel disease (IBD), colorectal cancer
8 and even sepsis [3-11]. Various studies have demonstrated the diagnostic potential of VOCs
9 in both pediatric and adult IBD populations, by analyzing VOCs deriving from urine, exhaled
10 breath and feces [6, 12-14]. The majority of studies on fecal VOCs have been performed
11 using Gas Chromatography/Mass Spectrometry (GC/MS), allowing for identification of
12 individual VOCs on molecular level. This technique is expensive, time-consuming and
13 requires specialized personnel and is therefore not suitable for utilization in a clinical setting
14 [15]. Pattern recognition based techniques, like electronic noses (eNose) and field
15 asymmetric ion mobility spectrometry (FAIMS), are examples of instruments that are lower
16 in expense and faster, allowing for their application as a non-invasive biomarker in clinical
17 practice. However, traditional eNoses contain sensors that are notorious for batch-to-batch
18 variation, fouling and ageing effects and sensors drift [14, 16]. Novel measurement of VOCs
19 using physical techniques, coupled with pattern recognition, like FAIMS, have a higher
20 sensitivity and minimal drift. It achieves separation by measuring the differences in mobility
21 of ionized molecules in high-electric fields.

22 Data on the potential influence of sampling and storage methods on fecal VOC profiles are
23 scarce. We aimed to evaluate effects of environmental factors and sampling conditions on
24 fecal VOC profiles, using FAIMS. In addition, we aimed to assess under which conditions an

1 optimal diagnostic accuracy could be obtained in the differentiation between pediatric IBD
2 and controls. This may lead to the development of rationale-based standardization protocols
3 on fecal VOC analysis, paving the way towards reliable comparisons between different study
4 outcomes, and implementation of VOC-based diagnostics in clinical practice.

5

6

1 **Methods**

2 Study design

3 This case-control study was performed at the outpatient clinic of the pediatric
4 gastroenterology departments in two tertiary referral hospitals, the VU University medical
5 center (VUmc) and the Emma Children's Hospital, Academic Medical Center (AMC), both
6 located in Amsterdam, The Netherlands.

7 Study participants

8 *Inflammatory bowel disease*

9 IBD subjects were selected from an existing cohort of *de novo* treatment-naïve pediatric
10 patients, consisting of 125 subjects (78CD, 47UC), aged 4 to 17 years, recruited between
11 October 2013 and July 2017 at the VU University Medical Centre (VUmc) and Academic
12 Medical Centre (AMC). Diagnosis of IBD was based on endoscopic, histologic and radiologic
13 findings, according to the revised Porto-criteria[17]. Localization and behavior of IBD were
14 classified during endoscopy, based on the Paris Classification[18]. Physician Global
15 Assessment (PGA) combined with levels of C-reactive protein (CRP) and fecal calprotectin
16 (FCP) were used as an index of the clinical disease activity [19, 20]. All IBD patients were
17 asked to collect a fecal sample prior to endoscopy and bowel preparation [14]. Inclusion
18 criteria also included sufficient fecal material for VOC analysis (3.4 grams per subject).
19 Exclusion criteria were use of antibiotics, probiotics or immunosuppressive therapy in the
20 three months prior to inclusion, a concomitant diagnosis of a gastrointestinal disease or
21 immunocompromised disease (i.e. HIV, leukemia) and abdominal surgery (except for
22 appendectomy). In addition, children with proven infectious colitis (parasites in stools, or
23 positive stool culture for *Salmonella spp.*, *Shigella spp.*, *Yersinia spp.*, *Campylobacter spp.*, or
24 toxigenic *Clostridium spp.*) were excluded.

1 *Healthy controls*

2 Healthy controls (HC) were children aged 4 to 17 years selected from elementary and high
3 schools in North-Holland, the Netherlands between June 2016 and December 2016. All
4 participants were asked to collect a fecal sample, and complete a questionnaire on
5 abdominal symptoms, bowel habits, including consistency of stool using the Bristol stool
6 chart, medication use and medical history[21]. Exclusion criteria for HC were similar to IBD,
7 with the addition of diagnosis of IBD and/or a functional gastrointestinal disorder according
8 to the Rome IV criteria based on the questionnaires.

9 *Matching procedure*

10 From the original cohort of 125 IBD patients, 106 were not eligible for this study due to
11 insufficient quantities of the fecal samples. A total of 17 IBD patients (15CD, 2UC) could be
12 matched on age at sample collection and gender with 25 participants in the HC group.

13 *Ethical considerations*

14 This study was approved by the Medical Ethical Review Committee (METc) of the VU
15 University Medical Centre (VUmc) under file number 2016.393, and by the local medical
16 ethical committee of the Emma Children's Hospital (AMC). Written informed consent was
17 obtained from all parents, and from the children in case of age over 12 years.

18 *Sample collection IBD and controls*

19 All study participants collected fresh fecal samples in a stool container (Stuhlgefäß 10ml,
20 Frickenhausen, Germany). Patients with IBD collected their fecal sample prior to endoscopy
21 and bowel lavage. Participants were instructed to store the fecal samples in the freezer at
22 home directly after collection. The samples were transported to the hospital in cooled

1 condition, using cooling elements or ice cubes. Directly upon arrival in the hospital the
2 samples were stored in the freezer (-24 °C) until analysis.

3 Sample preparation IBD and controls

4 The influence of fecal sample mass, number of thaw-freeze cycles, duration of storage in
5 room temperature, were assessed by comparing VOC-profiles derived from subsamples
6 taken from the original fecal sample of each HC and IBD subject. The subsamples were
7 weighted on a calibrated scale (Mettler Toledo, AT 261 Delta Range, Ohio, United States),
8 labelled and re-stored in a -24°C freezer until further handling. We compared the variables
9 of interest with our standard operating procedure (reference standard), defined as a mixture
10 of 500mg of feces, diluted with 10mL tap water and kept in room temperature for 10
11 minutes prior to analysis. These reference standard settings were chosen since they were
12 used in several previous studies on fecal VOC profiling in a range of gastroenterology
13 diseases and have provided us with positive results [14, 22].

14 Variables of interest

15 Effect of fecal sample mass on diagnostic accuracy of fecal VOC profiles was assessed by
16 comparing subsamples weighing 100mg and 300mg with the reference standard mass of
17 500mg.

18 The influence of the number of thaw-freeze cycles on the diagnostic accuracy was analyzed
19 by comparing the reference standard to subsamples, which underwent one, two and three
20 additional thaw-freeze cycles. For every additional cycle, the sample was kept at room
21 temperature for 10 minutes and subsequently kept on dry ice until the sample was frozen.

1 In order to assess the effect of duration of storage at room temperature on the diagnostic
2 accuracy, VOC from samples kept at room temperature (18 degrees) for 180 minutes were
3 compared to the reference standard. Variables of interest are presented in Table 1.

4 As described above, the effect of every variable on the diagnostic accuracy of fecal VOCs
5 were assessed by comparing IBD subjects with HC. In addition, we assessed the influence of
6 the variables on the VOC pattern. By combining the HC and IBD subjects, we were able to
7 compare the variables to the reference standard.

8 FAIMS analysis

9 For this study a commercially available FAIMS instrument (Lonestar[®], Owlstone, Cambridge,
10 UK) was used. Prior to the analyses, the FAIMS instrument was checked for contamination
11 using air and water blanks. The fecal samples were thawed to room temperature for ten
12 minutes prior to VOC analysis, and manually homogenized after diluting the fecal sample
13 with 10mL tap water by using a micropipette of 5000 μ l. The Lonestar[®] was setup as used in
14 previous studies[14, 22, 23]. To transport the sample headspace into the Lonestar[®],
15 compressed air (0.1MPa) was used as the carrier gas. This air meets the European
16 Pharmacopoeia criteria for medical air and its composition, pressure, temperature and water
17 density are checked for continuity regularly. When entering the Lonestar, this carrier gas is
18 filtered by a Carbon filter (Restek, Bellefote, VS). The flow rate was set on 2.0L/min, the
19 temperature for the sample holder was set at 35°C, for the lid at 70°C and 100°C for the filter
20 region. After every sample run, the Lonestar[®] was refreshed using 5mL of tap water.
21 Furthermore, the dispersion field was set between 0% and 100% (in the ratio of the high
22 electric field to low electric field) and passed through 51 equal settings. The compensation
23 voltage was set between +6V and -6V in 512 steps for each dispersion field. All samples were

1 analyzed randomly. Each fecal sample was analyzed three times subsequently, resulting in
2 three matrices, taking 540s to perform. In order to preclude environmental effects, the first
3 matrix was excluded from analyses since this measurement includes the heaspace gas
4 generated from both the sample and the environment (e.g. air in tubes). For the statistical
5 analysis, only the second matrix was used for optimal diagnostic potential. The third
6 measurement was made as a back-up file, but was not used in this study. The raw data
7 output was analyzed at the School of Engineering, University of Warwick, United
8 Kingdom[15].

9 Statistical analysis

10 The demographic data of each group (IBD patients and healthy controls) were compared
11 using the Man-Whitney-U test for non-parametric continues data, and the Fisher's exact test
12 for dichotomous data using SPSS Statistics (version 22, IBM, NY, USA). As previously
13 reported, the FAIMS produces high dimensional data in terms of the number of features and
14 covariates measured per sample. Therefore, a data compression was performed before
15 feature identification and classification. Each FAIMS data (sample) consists of 52224 data
16 points in a 2D matrix. Data compression was undertaken by applying a 2D discrete wavelet
17 transformation. For the variables of interest in which the accuracy to discriminate between
18 IBD and HC was assessed, feature selection and classifier training were performed to 90% of
19 data (training set) and class predictions were produced from 10% of the data set (test set), in
20 a 10-fold cross validation. The Wilcoxon-rank-sum test was used to calculate p-values in the
21 training sets to identify which features best for disease prediction. From this, 4 statistically
22 important features were used. Four classification algorithms were applied, Sparse Logistic
23 Regression, Random Forrest, Gaussian Process and Support Vector Machine. A receiver
24 operator characteristic (ROC) curve was created to predict the area under the curve (AUC),

1 p-values, sensitivity, specificity, positive predictive value (PPV), negative predictive value
2 (NPV) and diagnostic accuracy. For the influence of sampling method on VOC composition, in
3 which IBD and HC samples were combined and measurements of the same subjects samples
4 were repeated, data were analyzed using SPSS statistics 22 (IMB). The raw sensor data was
5 recombined with feature selection using the Wilcoxon rank sum tests. Paired t-tests were
6 performed to assess the potential of the features to discriminate between sample handling
7 methods. Scatterplots for the discrimination between samples were created for each
8 variable of interest. Axes depict the recombination of the raw sensor data by means of
9 features. Individual VOC profiles are illustrated as marked points. The intersection of the
10 lines deriving from the individual VOC profiles demonstrates the mean VOC profile of this
11 specific variable of interest.

12 Post hoc analyses

13 Our main target of this study was to assess the optimum sampling method to discriminate
14 between IBD and healthy controls based on VOC analyses by means of FAIMS. We found
15 there is a gap of knowledge on the effects of sample storage duration on VOC integrity.
16 Therefore, the effect of duration of storage in the freezer was analyzed by repeating
17 measurements from a previous study, conducted by van Gaal et al. in which fecal VOC
18 profiles of 36 *de novo* IBD patients were compared to 24 HC[14]. Based on the availability of
19 fecal samples from this study, 10 IBD (all CD) subjects and 10 HC could be included for
20 reassessment of VOC profiles. Storage time differed 20 months between the measurements,
21 with a median storage time in the freezer of 43 months for the first and 63 months for the
22 second measurements. Baseline characteristics and disease specifics of these study subjects
23 are described in Table 3. For both these analyses, the reference standard was used.

- 1 Diagnostic accuracy to detect IBD as well as the difference in VOC profile were assessed
- 2 using the statistical analyses described above.
- 3

1 **Results**

2 Baseline characteristics

3 Seventeen *de novo*, treatment-naïve pediatric IBD patients (15CD, 2UC) were selected from
4 the original cohort and were matched to 25 HC. Patient characteristics are shown in table 2.

5 There were no significant differences in age, sex and sample age between IBD and HC. The
6 range of the sample age was, however, larger in the IBD group compared to HC.

7 For the assessment of the influence of sample age on diagnostic accuracy, fecal samples of
8 10 IBD patients (CD only) and 10 HC were selected from the previous study and re-
9 measured[14]. Patients characteristics for this variable are described in Table 3.

10 Fecal VOC profiles per variable of interest

11 The results of the VOC analysis displayed per variable of interest are shown in Table 4. For
12 each analysis, the outcome of the Sparse Logistic Regression is noted. A complete overview
13 of the data generated by the four different classification models is given in supplemental
14 Table 1a-1d.

15 *Standard operating procedure*

16 By application of the reference standard settings, IBD and HC could be differentiated with
17 high accuracy (Accuracy, AUC (95% CI), Sensitivity, Specificity, PPV, NPV, P values; 0.93, 0.99
18 (0.96 – 1), 0.94, 0.96, 0.94, 0.96, 1.178e-10)(Table 4, Supp table 1a-1d, Figure 1). A typical
19 FAIMS pattern (flame) of both the IBD samples and control samples is depicted in Figure 2.

20 *Sample mass*

21 IBD could be differentiated from HC using a lower sample mass, but diagnostic accuracy
22 decreased compared to reference standard for both 300 mg per sample (Accuracy, AUC
23 (95% CI), Sensitivity, Specificity, PPV, NPV, P values; 0.77, 0.69 (0.52 – 0.86), 0.88, 0.44, 0.52,

1 0.85, 0.02101) and 100 mg per samples (Accuracy, AUC (95% CI), Sensitivity, Specificity, PPV,
2 NPV, P values; 0.70, 0.74 (0.59 – 0.90), 0.76, 0.72, 0.65, 0.82, 0.00364)(Table 4, Supp table
3 1a-1d, Figure 1).

4 *Thaw-freeze cycles*

5 After adding one extra thaw-freeze cycle to reference standard, a decrease in diagnostic
6 accuracy was observed (Accuracy, AUC (95%CI), sens, spec, PPV, NPV, P values; 0.61,
7 0.80(0.65-0.94), 0.76, 0.80, 0.72, 0.83) (Table 4, Supp table 1-4, Figure 1). After addition of a
8 second and third thaw-freeze cycle, differences in VOC profiles between IBD and HC
9 dissolved (Accuracy, AUC (95%CI), sens, spec, PPV, NPV, P values; 0.64, 0.56 (0.38 – 0.74),
10 0.76, 0.48, 0.50, 0.75, 0.7534 and 0.57, 0.50 (0.32 – 0.69), 0.47, 0.72, 0.53, 0.67, 0.5101
11 respectively)(Table 3, Supp table 1a-1d).

12 *Duration of storage at room temperature*

13 After keeping the samples at room temperature for 180 minutes prior to VOC analysis,
14 differences in VOC outcome between IBD and HC dissolved (Accuracy, AUC (95%CI), sens,
15 spec, PPV, NPV, P values; 0.60, 0.51 (0.32 – 0.70), 0.59, 0.68, 0.56, 0.71, 0.4596)(Table 4,
16 Supp table 1a-1d).

17 *Influence of sampling method on overall VOC composition*

18 In order to assess the influence of sampling conditions on the detected VOC patterns, HC
19 and IBD subjects were combined to form one single study group. The comparisons between
20 the four features are shown in Table 5. Differences in VOC pattern between sampling
21 methods are depicted in Figure 3. Both fecal samples weighing 300mg and 100mg
22 demonstrated a significantly different VOC profile compared to the standard reference mass
23 of 500mg (Feature 1,2 and 4: p-value <0.001 for and feature 3: p-value=0.027 for 300mg,

1 feature 1-4: p-value<0.0001 for 100mg). All of the variables in thaw-freeze cycles differed to
2 a similar extent from the reference standard (feature 1-4: p-value <0.0001 for all variables).
3 A similar difference as with the previous variables was seen when comparing the VOC
4 profiles of the reference standard to the VOC profiles of samples kept at room temperature
5 for 180 minutes prior to VOC analysis (feature 1-4: p-value<0.0001).

6 Post hoc analyses:

7 *Duration of storage in freezer*

8 The diagnostic accuracy to discriminate IBD from controls was not influenced by differences
9 in duration of storage time prior to VOC analysis (43 versus 63 months) (Accuracy, AUC
10 (95%CI), sens, spec, PPV, NPV, P values; 0.75, 0.75 (0.53 – 0.97), 0.70, 0.80, 0.78, 0.73,
11 0.0262 versus 0.75, 0.73 (0.49 – 0.97), 0.80, 0.70, 0.73, 0.78, 0.0376) (Table 4, Supp table 1a-
12 1d, Figure 1). The VOC composition of the two variables showed a significant difference in
13 three features (feature 1, 2 and 3 with p-values of <0.0001, <0.0001 and 0.021,
14 respectively)(Table 5, Figure 3).

15

1 **Discussion**

2 In the present study, VOC profiles and diagnostic accuracy were influenced significantly by
3 altering sampling conditions. Application of 500mg fecal sample mass diluted with 10mL,
4 thawed for 10 minutes prior to analysis after a single thaw-freeze cycle, showed the best
5 discriminative accuracy for differentiation of pediatric IBD and HC.

6 To our knowledge, this is the first published study to assess under which sampling conditions
7 an optimal accuracy can be obtained in the differentiation between pediatric IBD and
8 healthy state, by analyzing the fecal volatile metabolome using FAIMS. Studies assessing
9 optimization of sampling methods for fecal metabolome analyses have mainly focused on
10 gas chromatography – mass spectrometry (GC-MS), nuclear magnetic resonance
11 spectroscopy (NMR-spectroscopy) and liquid chromatography – mass spectrometry (LC-MS),
12 which are targeted and untargeted methods for identification of specific metabolites. These
13 studies may hypothetically provide guidance to standardization for the pattern-based FAIMS
14 technique. The results of this study will be discussed and compared to the available
15 literature in the following sections. Regarding sample mass, similar results to eNose, GC-MS,
16 NMR-spectroscopy and LC-MS studies on the fecal metabolome, in both humans and rats,
17 were found in our study, showing a difference between the use of 500mg from that of lower
18 masses [16, 24, 25]. Deda and colleagues have shown that the sample weight to volume
19 ratio has a major effect on the number and signal intensity of features detected in fecal
20 samples with GC-MS. This also applied for the spectral signal intensity when using NMR-
21 spectroscopy, and for the peak area intensity when using LC-MS[24]. The increased accuracy
22 to differentiate between IBD and HC when using a larger fecal mass, as observed in our
23 study, may be explained by this increase of richness in number and intensity of VOCs.

1 Observed differences in VOC profiles between fecal samples enduring one versus multiple
2 thaw-freeze cycles, are in line with previous research on VOC patterns using different eNose
3 devices [16, 26]. It could be hypothesized that these effects are caused by changes in
4 microbiota composition or function, although in a previous study no differences were found
5 in microbiota composition between analyses of fresh samples versus samples frozen at
6 minus 80 degrees and subsequently thawed prior to analysis [27]. A recent study suggested
7 a release of microbial intracellular contents following thaw-freeze cycles, possibly explaining
8 the effects of thaw-freeze cycles on VOC outcome[28]. In our study, it was shown that the
9 diagnostic accuracy decreased with the addition of one extra thaw-freeze cycle, and that IBD
10 could not be differentiated from HC after addition of multiple thaw-freeze cycles.
11 Consequently, future studies on fecal VOC should limit the number of thaw-freeze cycles
12 prior to analysis to a maximum of two.

13 Consistent with the results from a previous study on fecal VOCs using an eNose device, we
14 measured significant differences between fecal VOC profiles measured directly after thawing
15 (as used in the reference standard) and after 180 minutes stored at room temperature with
16 an accuracy of 0.84 [16]. Furthermore, it was demonstrated that the diagnostic accuracy
17 decreased when samples were kept at room temperature for 180 minutes (AUC= 0.53).
18 These results are in line with a previous study on the impact of storage conditions on crude
19 fecal samples measured by NMR-spectroscopy, showed that metabolic variation was
20 influenced by storage at room temperature and 4 °C[28]. The metabolic profiles of fecal
21 samples did not change after keeping the samples at room temperature for 1 hour.
22 However, samples stored for a longer time prior to the analyses gradually shifted. The
23 overall changes that were seen included decreased levels of fumarate, succinate, glutamate
24 and increased levels of methanol, phenylalanine and alanine and short chain fatty acids like

1 acetate, butyrate, propionate and valerate. To a lesser extent, the same shifts were seen in
2 samples kept at 4 °C, which indicates that the lower temperature slows down the impact on
3 sample integrity, resulting in less alterations in the metabolic profile. In another study
4 comparing VOC profiles of fecal samples kept at 1°C for 14 hours prior to GCMS analysis,
5 there were no significant changes in VOC profiles before and after 14 hours [25]. Since the
6 differences between IBD and HC in this study were analyzed by means of pattern-
7 recognition, specific metabolic alterations cannot be elucidated in this study. However, it
8 could be hypothesized that the unstable VOC composition when keeping the samples at
9 room temperature, is caused by ongoing fermentation by the fecal microbiota. Since
10 fermentative processes have shown to be reduced at lower temperature, this could explain
11 why VOC integrity remained stable when samples were kept at 1 and 4 degrees in previous
12 studies[28]. Another explanation is the emission of volatiles in the sample, and
13 contamination with background volatiles. Fermentation, emission and contamination could
14 be avoided by measuring the sample directly after collection. However, clinical
15 implementation of VOC analyses would then become a logistic challenge.

16 Literature on the influence of storage time of fecal VOCs is scarce. In a study assessing VOC
17 profiles of urine using a similar FAIMS method to the current study, a nine-month shelf-life
18 for urine samples was suggested after it was shown that chemical information was lost over
19 time, regarding both diversity and concentration of gas emission[29]. In addition, in a
20 previous study assessing the effect of sample age on serum VOCs measured by GCMS a
21 significant difference in metabolite composition was already seen after storage of three
22 weeks in the freezer [30]. In the current study, fecal VOC profiles for IBD, seem less
23 influenced by storage time compared to the previous studies on urine and serum, keeping a
24 similar (high) diagnostic accuracy after storage of 43 months and 63 months. Interestingly,

1 the samples chosen for this comparison, were used in a larger study by van Gaal et al. where
2 an area under the curve of 0.76 was found after a mean storage time of 23 months for the
3 IBD group (25CD, 21UC) and 39 months for the HC group[14]. The increase in the AUC of this
4 sub analysis, although analyzed at the same moment, can be explained by the fact that the
5 remaining samples only consisted of CD patients and HC. In the previous study, the AUC for
6 the differentiation between CD and HC was 0.90. There is, however, an important
7 consideration to this post hoc analyses. The diagnostic accuracy was only assessed after a
8 median storage duration of 43 and 63 months. Since there are no previous measurements, it
9 could be possible that massive changes in VOC composition have influenced diagnostic
10 accuracy in the initial months after collection. We cannot exclude this influence based on
11 this study.

12 The main strength of this study is that we used an IBD group and an HC group to assess not
13 only differences in VOC patterns between sampling methods, but also to assess the influence
14 on the diagnostic accuracy for disease detection. In addition, we used the same subjects'
15 samples for each of the analysis, accounting for various confounding factors of influence on
16 fecal VOCS (e.g. smoking habits, medication use, diet). During each experiment, the
17 remaining variables of interest were kept the same, ensuring optimal comparison based on
18 the variable of interest. Our study also has several limitations. Most importantly, for the
19 influence of storage time on diagnostic accuracy for IBD, we have made use of raw data of a
20 previous study and have re-assessed samples with sufficient sample mass. For this analyses
21 we were only able to include CD patients, and no UC. In addition, sample age differed
22 between groups, which could have influenced diagnostic accuracy by the influence of
23 metabolic degradation on VOC profiles at both measurements. Second, we have made use of
24 unfiltered and unsterilized tap water for sample dilution, and compressed medical air as

1 carrier gas. This protocol was chosen since it has been found a reliable sampling method for
2 the differentiation between various diseases and healthy controls based on fecal VOCs[31-
3 34]. To avoid VOC profile contamination, we have run air and water blanks which were
4 checked on contamination peaks, and met the cleanliness criteria. In addition, we have
5 analyzed the samples in a random order, and have excluded the first matrix of every sample
6 analyses to avoid air contamination. However, we cannot fully guarantee exclusion of VOC
7 contamination by differences in tap water composition between measurements. Third, we
8 have not explored the difference between the diagnostic accuracy when using fresh versus
9 frozen samples. As previously described, this seems of important influence on urine and
10 serum VOCs. However, since a diagnostic accuracy of 0.99 was found in this study, we
11 believe that freezing our samples has not significantly influenced our study outcomes. Last, it
12 is possible that optimized fecal sampling conditions are disease specific, and fecal VOC
13 biomarkers to diagnose IBD might have different sensitivity to variations in sampling method
14 compared to fecal VOC biomarkers for other gastrointestinal diseases. We did, however, find
15 significant differences in VOC profiles between sampling methods, emphasizing the
16 importance of the use of one standardized sampling method. Furthermore, it is important to
17 point out that we made use of pattern-recognition in this study, which complicates the
18 assessment of the influence of specific metabolites. We have chosen to validate specifically
19 the FAIMS method since this device is an easy-to-use tool which could be suitable for clinical
20 implementation [35].

21 This study highlights the need for one standardized methodology, in both research setting
22 and when using VOCs analysis as a (future) clinical tool. Based on this and previous study
23 results, we would like to suggest to use a standardized protocol with preferably fecal sample
24 masses of 500mg, no more than one thaw session prior to VOC analysis, and analyzation of

1 samples directly after thawing or, if impossible, keeping the samples frozen until further
2 analyses. Future studies should assess the difference in diagnostic accuracy between fresh
3 samples and frozen samples, and the influence of storage duration using multiple
4 measurement moments after sample collection.

5 In conclusion, this study showed a high discriminative accuracy to differentiate between IBD
6 and HC when using the standard operating procedure. It was shown that the use of less than
7 500mg, multiple thaw-freeze cycles, storage at room temperature and storage in freezer all
8 influence the diagnostic accuracy. We therefore suggest to use one standardized protocol
9 when performing fecal VOC analysis. In addition, further studies should focus on finding IBD
10 specific VOCs to allow for targeted pattern-recognition.

11

1 **Table 1. Variables of interest**

Variables of interest	Faecal sample mass (mg)	Thaw-freeze cycles (N)	Time out of freezer (min)
Reference standard	500	0	10
Mass variable 1	300	0	10
Mass variable 2	100	0	10
Thaw-freeze variable 1	500	1	10
Thaw-freeze variable 2	500	2	10
Thaw-freeze variable 3	500	3	10
180 minutes out of freezer	500	0	180
Storage time 1	500	0	10
Storage time 2	500	0	10

2

3 **Table 2. Baseline characteristics**

	Inflammatory bowel disease		Healthy controls (n=25)	<i>p-value</i>
	Crohn's disease (n=15)	Ulcerative colitis (n=2)		
Sex, male (n, [%])	10[66.7]	0[0]	14[56]	0.858
Age, yr (median[IQR])	13.0[11-15]	[10-16]*	12.0[4.0]	0.614
Sample age, mos (median [IQR])	11.0 [2-16]	[11-26]*	11.0[1.0]	0.376
<i>Physician's global assessment</i>				
Quiescent	1	0	NA	
Mild	9	2	NA	
Moderate	5	0	NA	
Severe	0	0	NA	
Faecal calprotectin (µg/g) (median[IQR])	1936[1006-2390]	[1800-2734]*	NA	
CRP (mg/l) (median[IQR])	24.3[2.5-42]	2.5**	NA	
¹ <i>Crohn's disease localization</i>				
Ileal (L1)	1	NA	NA	
Colonic (L2)	5	NA	NA	
Ileocolonic (L3)	6	NA	NA	
Proximal disease (L4)	1	NA	NA	
¹ <i>Crohn's disease behavior</i>				
B1 (NSNP)	14	NA	NA	
B1p (NSNP+p)	0	NA	NA	
B2 (S)	1	NA	NA	
B2p (S + p)	0	NA	NA	
B3 (P)	0	NA	NA	
B3p (P + p)	1	NA	NA	
¹ <i>Ulcerative colitis localization</i>				
Proctitis (E1)	NA	1	NA	
Left-sided (E2)	NA	1	NA	
Extensive (E3)	NA	0	NA	

4 Table 2. All values were obtained at study inclusion. Localization was obtained by ileocolonoscopy and
5 esophagogastroduodenoscopy before treatment initiation, and magnetic resonance enteroclysis.
6 Abbreviations: IQR, interquartile range; NA, not applicable; NSNP, non-stricturing non-penetrating; S,
7 stricturing; P, penetrating; p, peri-anal disease. ¹Based on Paris classification for inflammatory bowel disease
8 (24) *min-max values ** one missing value

9

10

11

1 **Table 3. Demographics sample analysis of the influence of duration time on VOC profiles**

	Crohn's disease (N=10)	Healthy controls (N=10)	p-value
Sex, male (n, [%])	5[50]	2[20]	0.350
Age, yr (median [IQR])	14.1[3.38]	7.8[3.72]	0.007
Sample age first measurement, mos (median[IQR])	23.4 [21-31]	52.2 [51-52.4]*	0.000
Sample age second measurement, mos (median[IQR])	43.2[41-51]	71 [70-72]*	0.000
<i>Physician's global assessment</i>			
Quiescent	0	NA	
Mild	0	NA	
Moderate	3	NA	
Severe	7	NA	
Fecal calprotectin (µg/g) (median[IQR])	1067[1218]	NA	
CRP (mg/l) (median[IQR])	29[29]	NA	
¹ <i>Crohn's disease localization</i>			
Ileal (L1)	0	NA	
Colonic (L2)	3	NA	
Ileocolonic (L3)	7	NA	
Proximal disease (L4)	5	NA	
¹ <i>Crohn's disease behavior</i>			
B1 (NSNP)	8	NA	
B1p (NSNP+p)	0	NA	
B2 (S)	0	NA	
B2p (S + p)	0	NA	
B3 (P)	1	NA	
B3p (P + p)	1	NA	

2 Table 3. All values were obtained at study inclusion. Localization was obtained by ileocolonoscopy and
3 esophagogastroduodenoscopy before treatment initiation, and magnetic resonance enteroclysis.
4 Abbreviations: IQR, interquartile range; NA, not applicable; NSNP, non-stricturing non-penetrating; S,
5 stricturing; P, penetrating; p, peri-anal disease. ¹Based on Paris classification for inflammatory bowel disease
6 (24) *one value missing.

7
8
9

1 **Table 4. Performance characteristics for the differentiation between IBD and Healthy for**
 2 **all of the variables of interest by faecal VOC analysis.**

Analysis	p-value	Accuracy	AUC (± 95% CI)	Cut- off	Sensitivity (± 95% CI)	Specificity (± 95% CI)	PPV	NPV
Reference standard (17IBD, 25HC)	1.178e-10	0.93	0.99 (0.96 - 1)	0.0014	0.94 (0.71 - 1)	0.96 (0.8 - 1)	0.94	0.96
Mass variable 1 (17IBD, 25HC)	0.02101	0.77	0.69 (0.52 - 0.86)	0.47	0.88 (0.64 - 0.99)	0.44 (0.24 - 0.65)	0.52	0.85
Mass variable 2 (17IBD, 25HC)	0.003642	0.70	0.74 (0.59 - 0.9)	0.44	0.76 (0.5 - 0.93)	0.72 (0.51 - 0.88)	0.65	0.82
Thaw-freeze variable 1 (17IBD, 25HC)	0.0004713	0.61	0.8 (0.65 - 0.94)	0.49	0.76 (0.5 - 0.93)	0.8 (0.59 - 0.93)	0.72	0.83
Thaw-freeze variable 2 (17IBD, 25HC)	0.7534	0.64	0.56 (0.38 - 0.74)	0.66	0.76 (0.5 - 0.93)	0.48 (0.28 - 0.69)	0.5	0.75
Thaw-freeze variable 3 (17IBD, 25HC)	0.5101	0.57	0.5 (0.32 - 0.69)	0.063	0.47 (0.23 - 0.72)	0.72 (0.51 - 0.88)	0.53	0.67
180 minutes out of freezer (17IBD, 25HC)	0.4596	0.60	0.51 (0.32 - 0.7)	0.13	0.59 (0.33 - 0.82)	0.68 (0.46 - 0.85)	0.56	0.71
Storage duration, first measurement (10CD vs 10 HC)	0.0262	0.75	0.75 (0.53 - 0.97)	0.47	0.7 (0.35 - 0.93)	0.8 (0.44 - 0.97)	0.78	0.73
Storage duration, second measurement (10CD vs 10 HC)	0.0376	0.75	0.73 (0.49 - 0.97)	0.58	0.8 (0.44 - 0.97)	0.7 (0.35 - 0.93)	0.73	0.78

3

4 Table 4. For each analysis, the best Sparse Logistic Regression outcome is shown. Sensitivities, specificities, p-
 5 values and AUCs are reported for the respective optimum cut-points.. Abbreviations: AUC, area under the
 6 curve; PPV: positive predictive value; NPV: negative predictive value. *Reference standard is defined as 500mg
 7 sample, diluted in 10mL water, thawed 10 minutes to room temperature.

8


1 Table 5. Paired feature analyses per variable of interest with corresponding p-values

Variables of interest	Feature 1 (p-value)	Feature 2 (p-value)	Feature 3 (p-value)	Feature 4 (p-value)
Sample mass (mg)				
500 vs 300	<0.0001	<0.0001	0.027	<0.0001
500 vs 100	<0.0001	<0.0001	<0.0001	<0.0001
Number of freeze-thaw cycles				
Measured directly vs one cycle	<0.0001	<0.0001	<0.0001	<0.0001
Measured directly vs two cycle	<0.0001	<0.0001	<0.0001	<0.0001
Measured directly vs three cycle	<0.0001	<0.0001	<0.0001	<0.0001
Kept at room temperature				
180 Minutes	<0.0001	<0.0001	<0.0001	<0.0001
Storage time				
First vs second measurement	<0.0001	<0.0001	0.021	0.825

2 Table 5. P-value < 0.05 is considered significant.

3


1 **Figure 1. Receiver operating characteristics for each variable of interest for the**
 2 **differentiation between inflammatory bowel disease and healthy state**



3 **Figure 1.** All receiver operating characteristic curves are obtained by Sparse Logistic Regression analyses.
 4 Abbreviations: AUC, area under the curve; IBD: Inflammatory bowel disease; HC: Healthy controls.

5


1 **Figure 2. Typical FAIMS pattern of patients with inflammatory bowel disease and healthy controls**



2 **Figure 2.** Depicted with a blue background are the positive ion currents. Depicted with a red
3 background are the negative ion currents.

4

1 **Figure 3. Scatterplot for the differentiation between sampling methods measured by field**
 2 **asymmetric ion mobility spectrometry**



3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13

Figure 3. Scatterplot for the differentiation between sampling methods measured by field asymmetric ion mobility spectrometry, including (a) sample mass; (b) number of freeze-thaw cycles; (c) 180 minutes out of freezer; (d) storage duration. Axes depicted are recombinations of the raw sensor data by means of feature selection using Wilcoxon rank sum analyses, creating four features per measurement. The marked points are the individual VOC signals. The intersection of the lines deriving from the individual signals are the mean VOC profile of that specific variable.

1 References

- 2 [1] R.P. Arasaradnam, N. Ouaret, M.G. Thomas, N. Quraishi, E. Heatherington, C.U. Nwokolo, K.D.
3 Bardhan, J.A. Covington, A novel tool for noninvasive diagnosis and tracking of patients with
4 inflammatory bowel disease, *Inflamm Bowel Dis*, 19 (2013) 999-1003.
- 5 [2] D.J.C. Berkhout, H.J. Niemarkt, M.A. Benninga, A.E. Budding, A.H. van Kaam, B.W. Kramer, C.M.
6 Pantophlet, M.M. van Weissenbruch, N.K.H. de Boer, T.G.J. de Meij, Development of severe
7 bronchopulmonary dysplasia is associated with alterations in fecal volatile organic compounds,
8 *Pediatr Res*, (2017).
- 9 [3] A. Smolinska, A.G. Bodelier, J.W. Dallinga, A.A. Masclee, D.M. Jonkers, F.J. van Schooten, M.J.
10 Pierik, The potential of volatile organic compounds for the detection of active disease in patients
11 with ulcerative colitis, *Aliment Pharmacol Ther*, (2017).
- 12 [4] A.G. Bodelier, A. Smolinska, A. Baranska, J.W. Dallinga, Z. Mujagic, K. Vanhees, T. van den Heuvel,
13 A.A. Masclee, D. Jonkers, M.J. Pierik, F.J. van Schooten, Volatile Organic Compounds in Exhaled Air as
14 Novel Marker for Disease Activity in Crohn's Disease: A Metabolomic Approach, *Inflamm Bowel Dis*,
15 21 (2015) 1776-1785.
- 16 [5] R.P. Arasaradnam, M. McFarlane, E. Daulton, J. Skinner, N. O'Connell, S. Wurie, S. Chambers, C.
17 Nwokolo, K. Bardhan, R. Savage, J. Covington, Non-invasive exhaled volatile organic biomarker
18 analysis to detect inflammatory bowel disease (IBD), *Dig Liver Dis*, 48 (2016) 148-153.
- 19 [6] I. Ahmed, R. Greenwood, B. Costello, N. Ratcliffe, C.S. Probert, Investigation of faecal volatile
20 organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease, *Aliment*
21 *Pharmacol Ther*, 43 (2016) 596-611.
- 22 [7] C.S. Probert, Role of faecal gas analysis for the diagnosis of IBD, *Biochemical Society transactions*,
23 39 (2011) 1079-1080.
- 24 [8] M.K. Nakhleh, H. Amal, R. Jeries, Y.Y. Broza, M. Aboud, A. Gharra, H. Ivgi, S. Khatib, S. Badarneh, L.
25 Har-Shai, L. Glass-Marmor, I. Lejbkovicz, A. Miller, S. Badarny, R. Winer, J. Finberg, S. Cohen-
26 Kaminsky, F. Perros, D. Montani, B. Girerd, G. Garcia, G. Simonneau, F. Nakhoul, S. Baram, R. Salim,
27 M. Hakim, M. Gruber, O. Ronen, T. Marshak, I. Doweck, O. Nativ, Z. Bahouth, D.Y. Shi, W. Zhang, Q.L.
28 Hua, Y.Y. Pan, L. Tao, H. Liu, A. Karban, E. Koifman, T. Rainis, R. Skapars, A. Sivins, G. Ancans, I.
29 Liepniece-Karele, I. Kikuste, I. Lasina, I. Tolmanis, D. Johnson, S.Z. Millstone, J. Fulton, J.W. Wells, L.H.
30 Wilf, M. Humbert, M. Leja, N. Peled, H. Haick, Diagnosis and Classification of 17 Diseases from 1404
31 Subjects via Pattern Analysis of Exhaled Molecules, *ACS Nano*, 11 (2017) 112-125.
- 32 [9] Y.Y. Broza, P. Mochalski, V. Ruzsanyi, A. Amann, H. Haick, Hybrid volatolomics and disease
33 detection, *Angew Chem Int Ed Engl*, 54 (2015) 11036-11048.
- 34 [10] A. Karban, M.K. Nakhleh, J.C. Cancilla, R. Vishinkin, T. Rainis, E. Koifman, R. Jeries, H. Ivgi, J.S.
35 Torrecilla, H. Haick, Programmed Nanoparticles for Tailoring the Detection of Inflammatory Bowel
36 Diseases and Irritable Bowel Syndrome Disease via Breathprint, *Adv Healthc Mater*, 5 (2016) 2339-
37 2344.
- 38 [11] S. Bosch, N. van Gaal, R.P. Zuurbier, J.A. Covington, A.N. Wicaksono, M.H. Biezeveld, M.A.
39 Benninga, C.J. Mulder, N.K.H. de Boer, T.G.J. de Meij, Differentiation Between Pediatric Irritable
40 Bowel Syndrome and Inflammatory Bowel Disease Based on Fecal Scent: Proof of Principle Study,
41 *Inflamm Bowel Dis*, (2018).
- 42 [12] C.S. Probert, S. Reade, I. Ahmed, Fecal volatile organic compounds: a novel, cheaper method of
43 diagnosing inflammatory bowel disease?, *Expert Rev Clin Immunol*, 10 (2014) 1129-1131.
- 44 [13] T.G. de Meij, N.K. de Boer, M.A. Benninga, Y.E. Lentferink, E.F. de Groot, M.E. van de Velde, A.A.
45 van Bodegraven, M.P. van der Schee, Faecal gas analysis by electronic nose as novel, non-invasive
46 method for assessment of active and quiescent paediatric inflammatory bowel disease: Proof of
47 principle study, *J Crohns Colitis*, (2014).
- 48 [14] N. van Gaal, R. Lakenman, J. Covington, R. Savage, E. de Groot, M. Bomers, M. Benninga, C.
49 Mulder, N. de Boer, T. de Meij, Faecal volatile organic compounds analysis using field asymmetric ion

1 mobility spectrometry: non-invasive diagnostics in paediatric inflammatory bowel disease, *J Breath*
2 *Res*, (2017).

3 [15] J.A. Covington, M.P. van der Schee, A.S. Edge, B. Boyle, R.S. Savage, R.P. Arasaradnam, The
4 application of FAIMS gas analysis in medical diagnostics, *The Analyst*, 140 (2015) 6775-6781.

5 [16] D.J. Berkhout, M.A. Benninga, R.M. van Stein, P. Brinkman, H.J. Niemarkt, N.K. de Boer, T.G. de
6 Meij, Effects of Sampling Conditions and Environmental Factors on Fecal Volatile Organic Compound
7 Analysis by an Electronic Nose Device, *Sensors (Basel, Switzerland)*, 16 (2016).

8 [17] A. Levine, S. Koletzko, D. Turner, J.C. Escher, S. Cucchiara, L. de Ridder, K.L. Kolho, G. Veres, R.K.
9 Russell, A. Paerregaard, S. Buderus, M.L. Greer, J.A. Dias, G. Veereman-Wauters, P. Lionetti, M.
10 Sladek, J. Martin de Carpi, A. Staiano, F.M. Ruemmele, D.C. Wilson, H. European Society of Pediatric
11 Gastroenterology, Nutrition, ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel
12 disease in children and adolescents, *J Pediatr Gastroenterol Nutr*, 58 (2014) 795-806.

13 [18] A. Levine, A. Griffiths, J. Markowitz, D.C. Wilson, D. Turner, R.K. Russell, J. Fell, F.M. Ruemmele,
14 T. Walters, M. Sherlock, M. Dubinsky, J.S. Hyams, Pediatric modification of the Montreal classification
15 for inflammatory bowel disease: the Paris classification, *Inflamm Bowel Dis*, 17 (2011) 1314-1321.

16 [19] D. Turner, A.R. Otley, D. Mack, J. Hyams, J. de Bruijne, K. Uusoue, T.D. Walters, M. Zachos, P.
17 Mamula, D.E. Beaton, A.H. Steinhart, A.M. Griffiths, Development, validation, and evaluation of a
18 pediatric ulcerative colitis activity index: a prospective multicenter study, *Gastroenterology*, 133
19 (2007) 423-432.

20 [20] J.S. Hyams, G.D. Ferry, F.S. Mandel, J.D. Gryboski, P.M. Kibort, B.S. Kirschner, A.M. Griffiths, A.J.
21 Katz, R.J. Grand, J.T. Boyle, et al., Development and validation of a pediatric Crohn's disease activity
22 index, *J Pediatr Gastroenterol Nutr*, 12 (1991) 439-447.

23 [21] S.J. Lewis, K.W. Heaton, Stool form scale as a useful guide to intestinal transit time, *Scand J*
24 *Gastroenterol*, 32 (1997) 920-924.

25 [22] M.K. Bomers, F.P. Menke, R.S. Savage, C.M. Vandenbroucke-Grauls, M.A. van Agtmael, J.A.
26 Covington, Y.M. Smulders, Rapid, accurate, and on-site detection of *C. difficile* in stool samples, *Am J*
27 *Gastroenterol*, 110 (2015) 588-594.

28 [23] J.A. Covington, L. Wedlake, J. Andreyev, N. Oualet, M.G. Thomas, C.U. Nwokolo, K.D. Bardhan,
29 R.P. Arasaradnam, The detection of patients at risk of gastrointestinal toxicity during pelvic
30 radiotherapy by electronic nose and FAIMS: a pilot study, *Sensors (Basel, Switzerland)*, 12 (2012)
31 13002-13018.

32 [24] O. Deda, A.C. Chatziioannou, S. Fasoula, D. Palachanis, N. Raikos, G.A. Theodoridis, H.G. Gika,
33 Sample preparation optimization in fecal metabolic profiling, *J Chromatogr B Analyt Technol Biomed*
34 *Life Sci*, 1047 (2017) 115-123.

35 [25] S.M. Reade, A. Aggio, R. Khalid, T. Pritchard DM. Ewer, AK. Probert CS., Optimisation of sample
36 preparation for direct SPME-GC-MS Analysis of murine and human faecal volatile organic compounds
37 for metabolomic studies, *Journal of Analytical & Bioanalytical techniques*, 5 (2014) 1000184.

38 [26] D.K. Chan, C.L. Leggett, K.K. Wang, Diagnosing gastrointestinal illnesses using fecal headspace
39 volatile organic compounds, *World J Gastroenterol*, 22 (2016) 1639-1649.

40 [27] F. Fouhy, J. Deane, M.C. Rea, O. O'Sullivan, R.P. Ross, G. O'Callaghan, B.J. Plant, C. Stanton, The
41 effects of freezing on faecal microbiota as determined using MiSeq sequencing and culture-based
42 investigations, *PLoS One*, 10 (2015) e0119355.

43 [28] J. Gratton, J. Phetcharaburanin, B.H. Mullish, H.R. Williams, M. Thursz, J.K. Nicholson, E. Holmes,
44 J.R. Marchesi, J.V. Li, Optimized Sample Handling Strategy for Metabolic Profiling of Human Feces,
45 *Anal Chem*, 88 (2016) 4661-4668.

46 [29] S. Esfahani, N.M. Sagar, I. Kyrou, E. Mozdiak, N. O'Connell, C. Nwokolo, K.D. Bardhan, R.P.
47 Arasaradnam, J.A. Covington, Variation in Gas and Volatile Compound Emissions from Human Urine
48 as It Ages, Measured by an Electronic Nose, *Biosensors (Basel)*, 6 (2016).

49 [30] S.L. Forbes, L. Rust, K. Trebilcock, K.A. Perrault, L.T. McGrath, Effect of age and storage
50 conditions on the volatile organic compound profile of blood, *Forensic Sci Med Pathol*, 10 (2014) 570-
51 582.

- 1 [31] N.v.G. Sofie Bosch, MD, Roy P. Zuurbier, James A. Covington, Alfian N. Wicaksono, Maarten H.
2 Biezeveld⁴, Marc A. Benninga, Chris J. Mulder, Nanne K.H. de Boer, Tim G.J. de Meij, Differentiation
3 between pediatric irritable bowel syndrome and inflammatory bowel disease based on fecal scent:
4 proof of principle study. , *Inflammatory Bowel Disease*, (2018) [In press].
- 5 [32] N. van Gaal, R. Lakenman, J. Covington, R. Savage, E. de Groot, M. Bomers, M. Benninga, C.
6 Mulder, N. de Boer, T. de Meij, Faecal volatile organic compounds analysis using field asymmetric ion
7 mobility spectrometry: non-invasive diagnostics in paediatric inflammatory bowel disease, *J Breath*
8 *Res*, 12 (2017) 016006.
- 9 [33] D.J.C. Berkhout, H.J. Niemarkt, M.A. Benninga, A.E. Budding, A.H. van Kaam, B.W. Kramer, C.M.
10 Pantophlet, M.M. van Weissenbruch, N.K.H. de Boer, T.G.J. de Meij, Development of severe
11 bronchopulmonary dysplasia is associated with alterations in fecal volatile organic compounds,
12 *Pediatr Res*, 83 (2018) 412-419.
- 13 [34] D.J.C. Berkhout, H.J. Niemarkt, M. Buijck, M.M. van Weissenbruch, P. Brinkman, M.A. Benninga,
14 A.H. van Kaam, B.W. Kramer, P. Andriessen, N.K.H. de Boer, T.G.J. de Meij, Detection of Sepsis in
15 Preterm Infants by Fecal Volatile Organic Compounds Analysis: A Proof of Principle Study, *J Pediatr*
16 *Gastroenterol Nutr*, 65 (2017) e47-e52.
- 17 [35] R. Arasaradnam, A. Wicaksono, H. O'Brien, H.M. Kocher, J.A. Covington, T. Crnogorac-Jurcevic,
18 Non-invasive Diagnosis of Pancreatic Cancer Through Detection of Volatile Organic Compounds in
19 Urine, *Gastroenterology*, (2017).

20